0000000000602495

AUTHOR

Stefano Cipolla

showing 3 related works from this author

STUDIO CLINICO RANDOMIZZATO SULL'EFFICACIA ANATOMO-FUNZIONALE A LUNGO TERMINE DEL TRATTAMENTO CHIRURGICO CON RANIBIZUMAB INTRAVITREALE ASSOCIATO ALLA…

Settore MED/30 - Malattie Apparato VisivoEdema maculare diabeticoEdema maculare diabetico; ranibizumab; fotocoagulazione laser maculare; foci iperreflettenti.fotocoagulazione laser maculareranibizumabfoci iperreflettenti.
researchProduct

Is Ranibizumab effective in stopping the loss of vision for Choroidal Neovascularization in Pathologic Myopia? A Long Term Follow-up Study

2010

Aim To assess the efficacy and safety of ranibizumab in the treatment of choroidal neovascularisation (CNV) caused by pathologic myopia (PM). Design Prospective, multicentre, interventional case series. Methods 40 eyes of 39 consecutive patients with PM and CNV were treated with ‘on demand’ intravitreal injection of ranibizumab 0.5 mg. Final best corrected visual acuity (BCVA) and its change from baseline were the main outcome measures. Changes in optical coherence tomography (OCT) central retinal thickness (CRT) were a secondary outcome. Results Mean age was 53±13 years and mean refractive error –13.5±6.5 D. Median follow-up was 13.3±2 (range 12–18) months. Fifteen eyes (37.5%) had previou…

MaleVisual Acuity/drug effectsRefractive errorgenetic structuresEye diseaseVisual AcuityVision disorderProspective StudiesFluorescein AngiographyMedicine(all)Neovascularisationmedicine.diagnostic_testAntibodies MonoclonalDrugsDiabetic retinopathyMiddle AgedFluorescein angiographySensory SystemsChoroidal neovascularizationmedicine.anatomical_structureMyopia DegenerativeIntravitreal InjectionsFemaleMyopia Degenerative/complicationsmedicine.symptomTomography Optical Coherencemedicine.drugAdultmedicine.medical_specialtyAntibodies Monoclonal HumanizedAntibodies Monoclonal/administration & dosageCellular and Molecular NeuroscienceRanibizumabOphthalmologymedicineHumansAgedbusiness.industryChoroidChoroidal Neovascularization/drug therapyOff-Label Usemedicine.diseaseChoroidal Neovascularizationeye diseasesOphthalmologyChoroidsense organsRanibizumabaged 80 and overbusinessFollow-Up Studies
researchProduct

Angioid streak-related choroidal neovascularization treated by intravitreal ranibizumab.

2010

PURPOSE The purpose of this study was to report the visual outcome of intravitreal therapy with ranibizumab of choroidal neovascularization secondary to angioid streaks after 1-year follow-up. METHODS Nine patients (age, 58 +/- 4 years; range, 53-65 years) were treated with off-label intravitreal injections of 0.3 mg ranibizumab. Primary outcomes were best-corrected visual acuity changes (Early Treatment Diabetic Retinopathy Study logarithm of the minimum angle of resolution and letters) and optical coherence tomography macular thickness changes. RESULTS Mean follow-up was 14 months (+/-2; range, 12-18 months). Mean visual acuity was 0.52 logarithm of the minimum angle of resolution and 30 …

MaleVascular Endothelial Growth Factor Amedicine.medical_specialtyVisual acuitygenetic structuresVisual AcuitymonoclonalAngiogenesis InhibitorsAntibodies Monoclonal HumanizedLoading doseChoroidal neovascularization; male; treatment outcome; injections; middle aged; vascular endothelial growth factor a; female; vitreous body; humans; retreatment; visual acuity; angiogenesis inhibitors; aged; angioid streaks; antibodies monoclonalInjectionsNeovascularizationOptical coherence tomographyOphthalmologyRanibizumabMedicineantibodiesHumansANTI-VEGFAgedintravitreal ranibizumabmedicine.diagnostic_testbusiness.industrySettore MED/30 - Malattie Apparato VisivoAntibodies MonoclonalGeneral MedicineDiabetic retinopathyMiddle Agedmedicine.diseaseeye diseasesChoroidal NeovascularizationVitreous BodyOphthalmologyAngioid streaksChoroidal neovascularizationTreatment OutcomeRetreatmentAngioid StreaksFemalemedicine.symptomRanibizumabbusinessAngioid streak-related choroidal neovascularizationmedicine.drugRetina (Philadelphia, Pa.)
researchProduct